Skip to main navigation
Skip to search
Skip to main content
Penn State Home
Help & FAQ
Link opens in a new tab
Search content at Penn State
Home
Researchers
Research output
Research units
Equipment
Grants & Projects
Prizes
Activities
Managing aromatase inhibitor-associated bone loss in breast cancer
Allan Lipton
, Michael Gnant
, Matti Aapro
Department of Medicine
Division of Hematology and Oncology
Penn State Cancer Institute
Research output
:
Contribution to journal
›
Review article
›
peer-review
2
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Managing aromatase inhibitor-associated bone loss in breast cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
5-year Survival
33%
Adjuvant Therapy
66%
Adverse Effects
33%
Aromatase Inhibitor-associated Bone Loss
100%
Aromatase Inhibitors
33%
Bisphosphonates
33%
Bone Loss
100%
Bone Metabolism
33%
Bone Metastasis
33%
Breast Cancer
100%
Death Rate
33%
Early Breast Cancer
33%
Europe
33%
Long-term Treatment
33%
Menopause
33%
Osteolytic Bone Lesions
33%
US FDA
33%
Zoledronic Acid
33%
Medicine and Dentistry
Adjuvant Endocrine Therapy
20%
Adjuvant Therapy
20%
Adverse Effect
20%
Aromatase Inhibitor
100%
Bisphosphonate
20%
Bone Lesion
20%
Bone Metastasis
20%
Bone Remodeling
20%
Breast Cancer
100%
Cancer Adjuvant Therapy
20%
Mortality Rate
20%
Osteolysis
100%
Survival Rate
20%
Zoledronic Acid
20%
Pharmacology, Toxicology and Pharmaceutical Science
Aromatase Inhibitor
100%
Bisphosphonic Acid Derivative
25%
Bone Lesion
25%
Bone Metastasis
25%
Breast Cancer
100%
Endocrine Therapy
25%
Malignant Neoplasm
25%
Mortality Rate
25%
Survival Rate
25%
Zoledronic Acid
25%